|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM364765593 |
| 003 |
DE-627 |
| 005 |
20250305112923.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202308477
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1215.xml
|
| 035 |
|
|
|a (DE-627)NLM364765593
|
| 035 |
|
|
|a (NLM)37985164
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Liu, Xueliang
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A Cardiac-Targeted Nanozyme Interrupts the Inflammation-Free Radical Cycle in Myocardial Infarction
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.01.2024
|
| 500 |
|
|
|a Date Revised 03.01.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Severe systemic inflammation following myocardial infarction (MI) is a major cause of patient mortality. MI-induced inflammation can trigger the production of free radicals, which in turn ultimately leads to increased inflammation in cardiac lesions (i.e., inflammation-free radicals cycle), resulting in heart failure and patient death. However, currently available anti-inflammatory drugs have limited efficacy due to their weak anti-inflammatory effect and poor accumulation at the cardiac site. Herein, a novel Fe-CurTA nanozyme is developed for targeted therapy of MI, which is generated by coordinating Fe3+ and anti-inflammatory drug curcumin (Cur) with further modification of tannic acid (TA). Such Fe-Cur@TA nanozyme exhibits excellent free radicals scavenging and anti-inflammatory properties by reducing immune cell infiltration, promoting macrophage polarization toward the M2-like phenotype, suppressing inflammatory cytokine secretion, and blocking the inflammatory free radicals cycle. Furthermore, due to the high affinity of TA for cardiac tissue, Fe-Cur@TA shows an almost tenfold greater in cardiac retention and uptake than Fe-Cur. In mouse and preclinical beagle dog MI models, Fe-Cur@TA nanozyme preserves cardiac function and reduces scar size, suggesting promising potential for clinical translation in cardiovascular disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a block of inflammation-free radical cycle
|
| 650 |
|
4 |
|a cardiac targeting
|
| 650 |
|
4 |
|a myocardial infarction
|
| 650 |
|
4 |
|a nanozyme
|
| 650 |
|
7 |
|a tannic acid
|2 NLM
|
| 650 |
|
7 |
|a Anti-Inflammatory Agents
|2 NLM
|
| 650 |
|
7 |
|a Free Radicals
|2 NLM
|
| 650 |
|
7 |
|a Polyphenols
|2 NLM
|
| 700 |
1 |
|
|a Chen, Binghua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Jingqi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Xuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dai, Xinfeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Yuqing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhou, Huayuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Lian-Ming
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Zhuang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Yu
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 2 vom: 08. Jan., Seite e2308477
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:2
|g day:08
|g month:01
|g pages:e2308477
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202308477
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 2
|b 08
|c 01
|h e2308477
|